SPY413.34+0.48 0.12%
DIA338.82+2.03 0.60%
IXIC13,971.71-24.39 -0.17%

BRIEF-Ampio Pharmaceuticals Details Early Positive Results For Inhaled Ampion In Covid-19 Respiratory Distress

· 03/16/2021 09:17
BRIEF-Ampio Pharmaceuticals Details Early Positive Results For Inhaled Ampion In Covid-19 Respiratory Distress

- Ampio Pharmaceuticals Inc AMPE.A:

  • AMPIO PHARMACEUTICALS DETAILS EARLY POSITIVE RESULTS FOR INHALED AMPION IN COVID-19 RESPIRATORY DISTRESS

  • AMPIO PHARMACEUTICALS INC - AMPION DEMONSTRATED IMPROVEMENT IN ALL-CAUSE MORTALITY IN COVID-19 PATIENTS COMPARED TO STANDARD OF CARE

  • AMPIO PHARMACEUTICALS INC - PATIENTS WHO RECEIVED AMPION REQUIRED LESS HOSPITALIZATION TIME.

  • AMPIO PHARMACEUTICALS INC - ADVERSE EVENTS WERE SAME BETWEEN AMPION AND STANDARD OF CARE

  • AMPIO PHARMACEUTICALS INC - NO DRUG-RELATED SERIOUS ADVERSE EVENTS HAVE BEEN REPORTED.

  • AMPIO PHARMACEUTICALS - PROVIDES UPDATES ON FORTHCOMING PHASE I CLINICAL TRIAL UTILIZING INHALED AMPION TO TREAT "LONG HAULER" COVID-19 SYMPTOMS

  • AMPIO PHARMACEUTICALS INC - TRIAL PROTOCOL IS BEING FINALIZED, WITH COMMENCEMENT OF STUDY EXPECTED BY MID-Q2 2021

Source text for Eikon: ID:nPn2VTqwka

Further company coverage: AMPE.A


((Reuters.Briefs@thomsonreuters.com;))